| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | A cost analysis of sorafenib for desmoid tumors |
| Autor/-in: | Johns, Michael S. Merritt, William T. Rhodes, Lori Ford, Candice N. Thompson, Mark Lee, William M. Sheldon, Yarrow Petrelli, Nicholas J. Tiesi, Gregory J. |
| et. al: | No |
| DOI: | 10.1177/10781552221077927 |
| Erschienen in: | Journal of Oncology Pharmacy Practice |
| Band(Heft): | 29 |
| Heft: | 3 |
| Seite(n): | 663 |
| Seiten bis: | 668 |
| Erscheinungsdatum: | 3-Feb-2022 |
| Verlag / Hrsg. Institution: | Sage |
| ISSN: | 1078-1552 1477-092X |
| Sprache: | Englisch |
| Schlagwörter: | Desmoid tumor; Cost analysis; Oncology; Sorafenib |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik 616: Innere Medizin und Krankheiten |
| Zusammenfassung: | Introduction: A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment. Utilizing these trial data, we performed a cost analysis of sorafenib efficacy through two years of treatment. Methods: Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day). Annual costs per progression and objective response were calculated. Radiologic progression and response were defined using RECIST criteria. Patients with disease progression were separately analyzed in two groups: both clinical and radiologic (CAR), and radiologic alone. Results: 84 previously randomized patients were analyzed (placebo: 35, sorafenib: 49). At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year. Two-year ARR was 17.5% with NNT 5.7 and estimated costs $1,285,052. Sorafenib patients experienced improved RECIST partial response rates at 1 and 2 years of 14.7% and 14.3%, with NNT 6.8 and 6.9, and costs of $766,938 and $1,556,433; respectively. Conclusion: For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient. Favorable RECIST outcomes were less likely and costlier. Patients should be informed of possible benefits of treatment versus potential financial burden. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/24912 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | School of Management and Law |
| Organisationseinheit: | Institut für Wealth & Asset Management (IWA) |
| Enthalten in den Sammlungen: | Publikationen School of Management and Law |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Johns, M. S., Merritt, W. T., Rhodes, L., Ford, C. N., Thompson, M., Lee, W. M., Sheldon, Y., Petrelli, N. J., & Tiesi, G. J. (2022). A cost analysis of sorafenib for desmoid tumors. Journal of Oncology Pharmacy Practice, 29(3), 663–668. https://doi.org/10.1177/10781552221077927
Johns, M.S. et al. (2022) ‘A cost analysis of sorafenib for desmoid tumors’, Journal of Oncology Pharmacy Practice, 29(3), pp. 663–668. Available at: https://doi.org/10.1177/10781552221077927.
M. S. Johns et al., “A cost analysis of sorafenib for desmoid tumors,” Journal of Oncology Pharmacy Practice, vol. 29, no. 3, pp. 663–668, Feb. 2022, doi: 10.1177/10781552221077927.
JOHNS, Michael S., William T. MERRITT, Lori RHODES, Candice N. FORD, Mark THOMPSON, William M. LEE, Yarrow SHELDON, Nicholas J. PETRELLI und Gregory J. TIESI, 2022. A cost analysis of sorafenib for desmoid tumors. Journal of Oncology Pharmacy Practice. 3 Februar 2022. Bd. 29, Nr. 3, S. 663–668. DOI 10.1177/10781552221077927
Johns, Michael S., William T. Merritt, Lori Rhodes, Candice N. Ford, Mark Thompson, William M. Lee, Yarrow Sheldon, Nicholas J. Petrelli, and Gregory J. Tiesi. 2022. “A Cost Analysis of Sorafenib for Desmoid Tumors.” Journal of Oncology Pharmacy Practice 29 (3): 663–68. https://doi.org/10.1177/10781552221077927.
Johns, Michael S., et al. “A Cost Analysis of Sorafenib for Desmoid Tumors.” Journal of Oncology Pharmacy Practice, vol. 29, no. 3, Feb. 2022, pp. 663–68, https://doi.org/10.1177/10781552221077927.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.